AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Other technologies
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in cardiac output monitoring use across nations
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in central venous catheter use across nations
Number of subjects: 12170
Study 26405576 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with L19-IL2
Number of subjects: 0
Study 26405584 — intervention group
Group type: EXPERIMENTAL
Intervention: DPX-Survivac vaccine in combination with metronomic cyclophosphamide
Number of subjects: 0
Study 26405584 — intervention group
Group type: EXPERIMENTAL
Intervention: DPX-Survivac vaccine
Number of subjects: 0
Study 26405686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (0.3 mg/d)
Number of subjects: 102
Study 26405686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (4 mg/d)
Number of subjects: 102
Study 26405686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26405686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (0.3 mg/d) and (4 mg/d)
Number of subjects: 102
Study 26407163 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CAP
Number of subjects: 430
Study 26407163 — intervention group
Group type: COMPARATOR
Intervention: Non-severe CAP
Number of subjects: 430
Study 26407235 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03084014 (gamma-secretase inhibitor)
Number of subjects: 0
Study 26407255 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-OPV-OPV (Group A)
Number of subjects: 0
Study 26407255 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-IPV-OPV (Group B)
Number of subjects: 0
Study 26407255 — intervention group
Group type: COMPARATOR
Intervention: OPV-OPV-OPV (Group C)
Number of subjects: 0
Study 26407818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI) 10 mg/kg plus Dacarbazine (DTIC) 850 mg/m(2) every 3 weeks for four doses (q3w × 4)
Number of subjects: 15
Study 26408329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic gastrointestinal surveillance (AGIS) biosensor; applied for 60 min before and continuously after abdominal surgery.
Number of subjects: 28
Study 26408329 — intervention group
Group type: EXPERIMENTAL
Intervention: AGIS biosensor; used to predict POI onset.
Number of subjects: 28
Study 26409297 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 50
Study 26409297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50
Study 26409610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 211
Study 26409610 — intervention group
Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 211
Study 26409628 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham coronary heart disease risk score Q4
Number of subjects: 3061
Study 26409628 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham cardiovascular risk score Q4
Number of subjects: 3061
Study 26409628 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham stroke risk profile Q4
Number of subjects: 3061
Study 26409628 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-scale Framingham risk scores
Number of subjects: 3061
Study 26409812 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization of pregnant women
Number of subjects: 0
Study 26409812 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of recommended vaccines
Number of subjects: 0
Study 26409812 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of women in high-risk settings in trials
Number of subjects: 0
Study 26409873 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Stressor scores, perceived stress, or depression scores
Number of subjects: 606
Study 26409873 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual stressors
Number of subjects: 606
Study 26409873 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 606
Study 26410176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose combined oral contraceptive (1.0-mg norethindrone acetate and 10-mcg ethinyl estradiol)
Number of subjects: 1581
Study 26410424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg every 3 weeks for four doses
Number of subjects: 20
Study 26410619 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight drugs targeting 18 molecular cohorts, specific drugs not mentioned.
Number of subjects: 0
Study 26410619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nextera next-generation sequencing platform designed by Illumina.
Number of subjects: 0
Study 26410619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-clinical justification for biomarker-drug combinations, molecular exclusion rules, and trumping strategy.
Number of subjects: 0
Study 26410619 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep genomic analysis of pre- and post-treatment biopsies, patient-derived xenograft models, longitudinal ctDNA collection.
Number of subjects: 0
Study 26411993 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels 9.1-10%
Number of subjects: 6313
Study 26411993 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels >10%
Number of subjects: 6313
Study 26411993 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin A1c (HbA1c) levels 8.1-9%
Number of subjects: 6313
Study 26411993 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients
Number of subjects: 6313
Study 26412290 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-week resistance exercise program (3 times/week; 3 sets, 6-8 repetitions at 75-80% of the 1-repetition maximum)
Number of subjects: 235
Study 26413873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL2 (1x10^6 U/m2 first month, 1.5x10^6 U/m2 following months)
Number of subjects: 5
Study 26413873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL2
Number of subjects: 5
Study 26413903 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) use
Number of subjects: 673
Study 26413903 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 673
Study 26413903 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >37 years
Number of subjects: 673
Study 26413903 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 673
Study 26413982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m² on day 1 and prednisone 100 mg/day on days 1-5 of each cycle
Number of subjects: 38
Study 26413982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-prednisone chemotherapy
Number of subjects: 38
Study 26415085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to maternal cancer with treatment (chemotherapy, radiotherapy, surgery, or other drug treatments)
Number of subjects: 129
Study 26415085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cancer diagnosis)
Number of subjects: 129
Study 26415085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to maternal cancer with or without treatment
Number of subjects: 129
Study 26415600 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with routine platelet reactivity testing
Number of subjects: 8582
Study 26415600 — intervention group
Group type: COMPARATOR
Intervention: Early generation DES
Number of subjects: 8582
Study 26415600 — intervention group
Group type: COMPARATOR
Intervention: No procedural intravascular ultrasound guidance
Number of subjects: 8582
Study 26415600 — intervention group
Group type: COMPARATOR
Intervention: Premature discontinuation of dual antiplatelet therapy
Number of subjects: 8582
Study 26415600 — intervention group
Group type: COMPARATOR
Intervention: High platelet reactivity on clopidogrel
Number of subjects: 8582
Study 26415600 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 0 to 3 modifiable risk factors
Number of subjects: 8582
Study 26415764 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastmilk intake
Number of subjects: 0
Study 26415764 — intervention group
Group type: COMPARATOR
Intervention: Control group (GDM children)
Number of subjects: 0
Study 26415945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spasticity
Number of subjects: 328
Study 26415945 — intervention group
Group type: COMPARATOR
Intervention: Patients without spasticity
Number of subjects: 328
Study 26415998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Functional Index (TFI)
Number of subjects: 294
Study 26416092 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) in eyes with IRD
Number of subjects: 30
Study 26416092 — intervention group
Group type: COMPARATOR
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) in normal eyes
Number of subjects: 30
Study 26416092 — intervention group
Group type: COMPARATOR
Intervention: Interobserver agreement in normal eyes
Number of subjects: 30
Study 26416092 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in eyes with IRD
Number of subjects: 30
Study 26416092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone spacing measures correlation between visits for both groups
Number of subjects: 30
Study 26416092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone spacing measures from fellow eyes of the same subject
Number of subjects: 30
Study 26416471 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV
Number of subjects: 118
Study 26416471 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir
Number of subjects: 118
Study 26416513 — intervention group
Group type: EXPERIMENTAL
Intervention: PNH/SAA subgroup
Number of subjects: 282
Study 26416513 — intervention group
Group type: COMPARATOR
Intervention: Classic PNH subgroup
Number of subjects: 282
Study 26416513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subgroups
Number of subjects: 282
Study 26416564 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m² bid, Paclitaxel 60 mg/m²/week, Carboplatin AUC of 6
Number of subjects: 54
Study 26416574 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Pathway for Primary Palliative Care (CPPPC) implemented by general practitioners (GPs).
Number of subjects: 5
Study 26416574 — intervention group
Group type: COMPARATOR
Intervention: Patient populations of participating GPs.
Number of subjects: 5
Study 26416780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-infusion meropenem (40 mg/kg every 8 h as a 3 h infusion)
Number of subjects: 30
Study 26416780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-infusion meropenem
Number of subjects: 30
Study 26416780 — intervention group
Group type: COMPARATOR
Intervention: 0.5 h infusion
Number of subjects: 30
Study 26416813 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet (MD)
Number of subjects: 153
Study 26416813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-based diets
Number of subjects: 153
Study 26416813 — intervention group
Group type: COMPARATOR
Intervention: Omnivore diet
Number of subjects: 153
Study 26416896 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT)
Number of subjects: 47
Study 26416897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 476
Study 26416897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 476
Study 26416897 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 476
Study 26417268 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted dietary weight-loss intervention for six months
Number of subjects: 47
Study 26417268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin C
Number of subjects: 47
Study 26417268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary tocopherols
Number of subjects: 47
Study 26417268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene
Number of subjects: 47
Study 26417987 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomodulatory metronomic therapy
Number of subjects: 0
Study 26418126 — intervention group
Group type: COMPARATOR
Intervention: No EEG suppression
Number of subjects: 727
Study 26418126 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression (divided into quartiles based on duration)
Number of subjects: 727
Study 26418126 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression (per 1-minute increase)
Number of subjects: 727
Study 26418126 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG suppression
Number of subjects: 727
Study 26418191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (140 μg/kg/min) infusion for 1-2 min
Number of subjects: 648
Study 26418430 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for removing thermosensitive acrylic punctal plugs (involves local anesthesia, lid clamp, and microforceps if necessary)
Number of subjects: 14
Study 26418443 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging in MacTel 2 patients
Number of subjects: 8
Study 26418443 — intervention group
Group type: COMPARATOR
Intervention: Normative database
Number of subjects: 8
Study 26419191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid 3000 mg oral dose
Number of subjects: 6
Study 26419198 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 inactivated vaccine
Number of subjects: 0
Study 26419198 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation or analgesia (continuous infusion, intermittent doses, or both)
Number of subjects: 6680
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 6680
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 6680
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockers
Number of subjects: 6680
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SH-GA (opioids, sedatives-hypnotics, general anaesthetics)
Number of subjects: 6680
Study 26420017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessments
Number of subjects: 6680
Study 26420235 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg orally once daily plus erlotinib 150 mg orally once daily
Number of subjects: 11
Study 26420235 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg/day
Number of subjects: 11
Study 26420235 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax and erlotinib combination
Number of subjects: 11
Study 26420684 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 302
Study 26420684 — intervention group
Group type: COMPARATOR
Intervention: MTX + anti-TNF
Number of subjects: 302
Study 26420684 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX, sulfasalazine, hydroxychloroquine)
Number of subjects: 302
Study 26420684 — intervention group
Group type: COMPARATOR
Intervention: anti-TNF
Number of subjects: 302
Study 26420854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal vaccination with TA-HPV
Number of subjects: 0
Study 26420854 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of TA-HPV
Number of subjects: 0
Study 26420969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic ultrasonography (EUS) performed within 48 hours of admission; mean procedure time 14.7 min (range 9-34 min)
Number of subjects: 71
Study 26421426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days)
Number of subjects: 92
Study 26422550 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic taping
Number of subjects: 40
Study 26422550 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 40
Study 26422550 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft brace
Number of subjects: 40
Study 26422550 — intervention group
Group type: EXPERIMENTAL
Intervention: All three methods (kinesiotaping, non-elastic taping, soft brace)
Number of subjects: 40
Study 26423260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin (with potential escalation to 10 mg)
Number of subjects: 2
Study 26423374 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus Elbasvir 50 mg once daily for 12 weeks
Number of subjects: 218
Study 26423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG) in nonobese mothers
Number of subjects: 937
Study 26423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG) in obese mothers
Number of subjects: 937
Study 26423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy adiposity
Number of subjects: 937
Study 26423388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational fasting plasma glucose (FPG)
Number of subjects: 937
Study 26423389 — intervention group
Group type: COMPARATOR
Intervention: High-caloric mixed meal
Number of subjects: 30
Study 26423389 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 30
Study 26423389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic γATP, inorganic phosphate (Pi), and fat content (hepatocellular lipids) measured with (31)P/(1)H magnetic resonance spectroscopy
Number of subjects: 30
Study 26423389 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body insulin sensitivity (M value) assessed with hyperinsulinemic-euglycemic clamps
Number of subjects: 30
Study 26423721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment based on Clinical Dementia Rating (CDR) scale (MCI-CDR)
Number of subjects: 102
Study 26423721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment based on neurocognitive battery (MCI-NC)
Number of subjects: 102
Study 26423721 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-CDR, MMSE, and Lawton IADL score
Number of subjects: 102
Study 26423721 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-NC, CDR sum of boxes, MMSE, and Lawton IADL score
Number of subjects: 102
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of fruits and vegetables
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of β-carotene
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of vitamin C
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of α-tocopherol
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of EPA
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of DHA
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of ALA
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentration
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplements (β-carotene, vitamin C, α-tocopherol)
Number of subjects: 86
Study 26423734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 86
Study 26423739 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's food neophobia
Number of subjects: 249
Study 26423739 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's sensory behaviors (SBs)
Number of subjects: 249
Study 26423739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 249
Study 26423749 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥125mcg/day of levothyroxine
Number of subjects: 500
Study 26423749 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥200mcg/day of levothyroxine
Number of subjects: 500
Study 26423811 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg) three times per week every other week for 8 weeks
Number of subjects: 15
Study 26423811 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg)
Number of subjects: 15
Study 26423856 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Number of subjects: 180
Study 26423989 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (600 mg twice daily)
Number of subjects: 276
Study 26423989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 26424330 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 3152
Study 26424605 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DENV-2 strain DEN2Δ30
Number of subjects: 30
Study 26424605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue human infection model (DHIM) developed by Walter Reed Army Institute of Research (WRAIR)
Number of subjects: 30
Study 26425874 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected lungs (stress index values within 0.95 to 1.05 range)
Number of subjects: 14
Study 26425874 — intervention group
Group type: COMPARATOR
Intervention: Nonprotected lungs (stress index values greater than 1.05 or less than 0.95)
Number of subjects: 14
Study 26425874 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected lungs
Number of subjects: 14
Study 26425874 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress index during EVLP
Number of subjects: 14
Study 26425877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant circulating CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76
Study 26425877 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage and absolute number of CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76
Study 26425877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant recipient circulating CD4+CD127lo/-TNFR2+ Treg cells
Number of subjects: 76
Study 26426575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 30
Study 26427420 — intervention group
Group type: EXPERIMENTAL
Intervention: MERTK mutations
Number of subjects: 0